Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring of isavuconazole in special populations
ChiCTR2600116582Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isavuconazole in Invasive mold disease (IMD) and invasive mycoses, sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Plasma concentration of isavuconazole during the loading dose phase, Plasma concentration of isavuconazole during CRRT and/or ECMO and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
isavuconazole
03
Conditions
Invasive mold disease (IMD)invasive mycoses
Beyond the preview
Go deeper on ChiCTR2600116582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116582.